Prevention of Oral Mucositis in Children and Adolescents Undergoing Hematopoietic Cell transplant Using Photobiomodulation Therapy (215)

11:30 am – 12:30 pm Friday, October 29

Oral mucositis is a significant and common toxicity experienced by patients who receive high-dose chemotherapy as a preparatory regimen for a hematopoietic cell transplant (HCT). Furthermore, oral mucositis has been reported as the single most debilitating side effect reported by patients undergoing HCT.

The use of intra-oral photobiomodulation therapy (PBM) in adult patients who develop therapy-related mucositis is included in the international mucositis guidelines, with pediatric evidence suggesting its use in preventing oral mucositis during HCT and head/neck radiotherapy. This presentation will describe the feasibility and efficacy of PBM in reducing oral mucositis in children and adolescents at risk for grade 3 oral mucositis who are undergoing an allogeneic HCT. Data will be presented describing the outcomes of our light therapy intervention, which has treated 40 children and adolescents who received high-dose chemotherapy, followed by HCT. The feasibility and efficacy of light therapy will be presented, as well as outcome data on grade and duration of mucositis, pain medications, days of nutritional support, and blood and oral cultures, to day +20 or engraftment (whichever occurs first). The nurse will understand the mechanism of light therapy, as well as barriers to facilitation in therapy implementation. This method will be described as providing an evidence-based method for oral mucositis reduction.

Belinda Mandrell, PhD RN CNP FAAN
CNE Hours: